Additional Issues. Within ten (10) Business Days after the receipt of the Arbitration Request, the other Party may, by written notice, add additional issues for resolution.
Appears in 4 contracts
Samples: License, Development, and Commercialization Agreement, License, Development, and Commercialization Agreement (Anacor Pharmaceuticals Inc), License Agreement (Novacea Inc)
Additional Issues. Within ten thirty (1030) Business Days business days after the receipt of the Arbitration Request, the other Party may, by written notice, add additional issues for resolution.
Appears in 4 contracts
Samples: License Agreement (Radius Health, Inc.), License Agreement (Radius Health, Inc.), License Agreement (Radius Health, Inc.)
Additional Issues. Within ten (10) Business Days business days after the receipt of the Arbitration Request, the other Party Parties may, by written notice, add additional issues for resolution.
Appears in 4 contracts
Samples: Pre Pay Agreement (GlassBridge Enterprises, Inc.), Settlement Agreement, Settlement Agreement (GlassBridge Enterprises, Inc.)
Additional Issues. Within ten (10) Business Days business days after the receipt of the Arbitration Request, the other Party may, by written notice, add additional issues for resolution.
Appears in 3 contracts
Samples: Co Development and Commercialization Agreement (Protein Design Labs Inc/De), Collaboration Agreement (Stressgen Biotechnologies Corp), License and Supply Agreement (Synovics Pharmaceuticals)
Additional Issues. Within ten *** (10***) Business Days business days after the receipt of the Arbitration Request, the other Party may, by written notice, add additional issues for resolutionto be resolved.
Appears in 1 contract
Samples: Development and License Agreement (Biocryst Pharmaceuticals Inc)
Additional Issues. Within ten (10) Business Days business days after the receipt of the Arbitration Request, the other Party may, by written notice, add additional issues for resolution.. 140. CONFIDENTIAL TREATMENT
Appears in 1 contract
Samples: Co Development and Commercialization Agreement (PDL Biopharma, Inc.)
